| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b18da5196d0dd17ed769b4aa576b1831 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6147258698de8596fd17e92e815a8852
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b864370c6c670b7a15a7f58fe16994ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae4440fa14611c971620d26f346184e6 |
| publicationDate |
2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114853909-A |
| titleOfInvention |
Design, Preparation and Use of Novel IL-2, INFα and Fc Fusion Proteins |
| abstract |
The present invention comprises the remodeling of human interleukin-2 (IL-2) and interferon alpha (IFNalpha); the fusion protein formed by IL-2, INFalpha or IL-2/INFalpha double factor and Fc after remodeling; And the design, preparation and use of these fusion proteins; mutant IL-2 and mutant INFα (dual factor) are fused to the N-terminus or C-terminus of Fc respectively; mutant IL-2 is fused to the N-terminus or C-terminus of Fc The mutant INFα was fused to the N-terminus or C-terminus of Fc respectively; L234A/L235A mutations were introduced into the Fc segment at the same time to reduce the binding ability to the receptor FcgRIII; M252Y/S254T/T256E mutations were introduced to prolong the half-life of the protein; The invention changes the binding ability of IL-2 and its receptor, INFα and its receptor through gene mutation, obtains a mutant better than the wild type, improves the binding ability with NK cells and CD8+T cell receptors, and solves the problem of current It has the disadvantages of weak drug specificity and large side effects. |
| priorityDate |
2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |